Introduction
Schizophrenia is a severe and persistent mental health disorder that affects more than 23 million people worldwide (WHO 2018) and is associated with cognitive dysfunction and poor functional capacity in nearly all domains (Harvey and Strassing, Reference Harvey and Strassing2012). People with schizophrenia also have a 20% shorter life span than people in the general population (Newman and Bland, Reference Newman and Bland1991), and the mortality gap between people with schizophrenia and the general population is increasing (Saha et al., Reference Saha, Chant and McGrath2007). Although rates of completed suicide are higher in people with schizophrenia than in the general population (Baxter and Appleby, Reference Baxter and Appleby1999), the greatest contributor to the heightened risk of premature death in people with schizophrenia is early mortality due to chronic diseases (Ösby et al., Reference Ösby, Correia, Brandt, Ekbom and Sparén2000).
The largest contributors to chronic disease-related deaths in people with schizophrenia are cardiovascular diseases and cancer (Crump et al., Reference Crump, Winkleby, Sundquist and Sundquist2013; Polednak, Reference Polednak2014; Westman et al., Reference Westman, Eriksson, Gissler, Hällgren, Prieto, Bobo, Frye, Erlinge, Alfredsson and Ösby2018). Observational research conducted over the past three decades has consistently linked schizophrenia with an increased risk of cancer mortality (Zhuo et al., Reference Zhuo, Tao, Jiang, Lin and Shao2017; Tanskanen et al., Reference Tanskanen, Tiihonen and Taipale2018). Studies have shown that the occurrence of risk factors for cancer, such as heavy smoking, drug and alcohol abuse, poor diet and lack of exercise, in people with schizophrenia is higher than in the general population (Brown et al., Reference Brown, Birtwistle, Roe and Thompson1999; Hartz et al., Reference Hartz, Pato, Medeiros, Cavazos-Rehg, Sobell, Knowles, Bierut and Pato2014; Hunt et al., Reference Hunt, Large, Cleary, Lai and Saunders2018; Jakobsen et al., Reference Jakobsen, Speyer, Nørgaard, Karlsen, Hjorthøj, Krogh, Mors, Nordentoft and Toft2018). People with schizophrenia may also have compromised access to general health care resources (Brown et al., Reference Brown, Birtwistle, Roe and Thompson1999; Mitchell et al., Reference Mitchell, Lord and Malone2012).
However, research results on the relationship between schizophrenia and cancer incidence have been less consistent than results on the relationship between schizophrenia and cancer mortality (Hodgson et al., Reference Hodgson, Wildquist and Busche2010). A number of early studies reported unexpectedly low rates of cancer in people with schizophrenia despite an over-representation of cancer risk factors (Mortensen, Reference Mortensen1989, Reference Mortensen1994; Gulbinat et al., Reference Gulbinat, Dupont, Jablensky, Jensen, Marsella, Nakane and Sartorius1992; Cohen et al., Reference Cohen, Dembling and Schorling2002), which gave rise to the hypothesis that schizophrenia or the medications used to treat it may protect against cancer risk (Mortensen, Reference Mortensen1989; Gulbinat et al., Reference Gulbinat, Dupont, Jablensky, Jensen, Marsella, Nakane and Sartorius1992; Fond et al., Reference Fond, Macgregor, Attal, Larue, Brittner, Ducasse and Capdevielle2012). A recent meta-analysis of 16 observational studies – with a total of 480 356 participants and 14 999 cases of cancer – reported a statistically significant but small decrease in the overall risk of cancer in patients with schizophrenia (RR 0.90, 95% CI 0.81–0.99) (Li et al., Reference Li, Li, Yu, Zheng, Sun, Lu, Zhang, Li and Bi2018). However, the results of individual studies are inconsistent. Some report lower (Barak et al., Reference Barak, Achiron, Mandel, Mirecki and Aizenberg2005; Dalton et al., Reference Dalton, Mellemkjaer, Thomassen, Mortensen and Johansen2005; Grinshpoon et al., Reference Grinshpoon, Barchana, Ponizovsky, Lipshitz, Nahon, Tal, Weizman and Levav2005; Chou et al., Reference Chou, Tsai, Su and Lee2011; Ji et al., Reference Ji, Sundquist, Sundquist and Hemminki2012; Whitley et al., Reference Whitley, Batty, Mulheran, Gale, Osborn, Tynelius and Rasmussen2012; Kisely et al., Reference Kisely, Forsyth and Larence2016) while others report similar (Saku et al., Reference Saku, Tokudome, Ikeda, Kono, Makimoto, Uchimura, Mukai and Yoshimura1995; Oksbjerg Dalton et al., Reference Oksbjerg Dalton, Munk Laursen, Mellemkjaer, Johansen and Mortensen2003; Goldacre et al., Reference Goldacre, Kurina, Wotton, Yeates and Seagroat2005; Truyers et al., Reference Truyers, Buntinx, De Lepeleire, De Hert, Van Winkel, Aertgeerts, Bartholomeeusen and Lesaffre2011; Lin et al., Reference Lin, Lane, Chen, Wu, Wu and Wu2013a; Osborn et al., Reference Osborn, Limburg, Walters, Petersen, King, Green, Watson and Nazareth2013; Raviv et al., Reference Raviv, Laufer, Baruch and Barak2014; Brink et al., Reference Brink, Green, Bojesen, Lamberti, Conwell and Andersen2019) or higher (Ananth and Burnstein, Reference Ananth and Burnstein1977; Lawrence et al., Reference Lawrence, Holman, Jablensky, Threlfall and Fuller2000; Lichtermann et al., Reference Lichtermann, Ekelund, Pukkala, Tanskanen and Lönnqvist2001) overall cancer risks in people with diagnosed schizophrenia than in control populations.
The discrepant findings from studies of schizophrenia and cancer incidence may be explained by inter-study heterogeneity and failure to account for the numerous factors that contribute to it (Li et al., Reference Li, Li, Yu, Zheng, Sun, Lu, Zhang, Li and Bi2018). In particular, investigations of schizophrenia and the risk of multiple cancer types combined as a single endpoint have been criticised because individual types of cancer have heterogeneous risk factors, aetiologies and prognoses (Hodgson et al., Reference Hodgson, Wildquist and Busche2010). As such, the risk of specific cancer types in people with schizophrenia has been the focus of several more recent epidemiological studies. In general, meta-analyses of studies that have focused on individual types of cancer suggest that the risk of breast cancer may be increased in people with schizophrenia (Catala-Lopez et al., Reference Catala-Lopez, Suarez-Pinilla, Suarez-Pinilla, Valderas, Gómez-Beneyto, Martinez, Balanzá-Martínez, Climent, Valencia, McGrath, Crespo-Facorro, Sanchez-Moreno, Vieta and Tabarés-Seisdedos2014; Chou et al., Reference Chou, Tsai, Wu and Shen2016; Xiping et al., Reference Xiping, Shuai, Feijiang, Bo, Shifeng and Qihui2018; Zhuo and Triplett, Reference Zhuo and Triplett2018), although results are inconsistent (Li et al., Reference Li, Li, Yu, Zheng, Sun, Lu, Zhang, Li and Bi2018), and data on the associations between schizophrenia and other cancer types are equivocal or more sparse (Busche and Hodgson, Reference Busche and Hodgson2010; Xu et al., Reference Xu, Chen, Kong, Zhang, Hu, Chen, Li and Zhuo2017; Li et al., Reference Li, Li, Yu, Zheng, Sun, Lu, Zhang, Li and Bi2018; Zhuo et al., Reference Zhuo, Zhuang, Gao and Triplett2019). Therefore, additional studies of the effects of schizophrenia on site-specific cancer risk are needed to achieve a more comprehensive understanding of the incidence of lifestyle-related cancers in people with schizophrenia, and to confirm or identify new associations with specific cancer subtypes. This information is important for informing efforts to develop effective disease-specific preventive interventions and programmes (Chou et al., Reference Chou, Tsai, Wu and Shen2016).
We conducted a population-based study of the incidence of seven common types of cancer in 111 306 people with a hospital diagnosis of schizophrenia, using three comprehensive registries in Sweden and accounting for the effects of age, sex and calendar time. We chose to study a number of specific cancer sites either characterised by high mortality in the Swedish population or an association with adverse lifestyle factors that are also over-expressed in people with schizophrenia (e.g. smoking, alcohol consumption, physical inactivity and poor diet), or both (Regier et al., Reference Regier, Fermer, Rae, Locke, Keith, Judd and Goodwin1990; Hung et al., Reference Hung, Yang, Huang, Lung, Lin, Chen, Kuo and Chen2014; Maremmani et al., Reference Maremmani, Bacciardi, Gehring, Cambioli, Schutz, Jang and Drausz2017; Vancamfort et al., Reference Vancampfort, Firth, Schuch, Rosenbaum, Mugisha, Hallgren, Probst, Ward, Gaughran, De Hert, Carvalho and Stubbs2017; Firth et al., Reference Firth, Stubbs, Teasdale, Ward, Veronese, Shivappa, Hebert, Berk, Yung and Sarris2018; Jakobsen et al., Reference Jakobsen, Speyer, Nørgaard, Karlsen, Hjorthøj, Krogh, Mors, Nordentoft and Toft2018). We hypothesised that cancers associated with these specific lifestyle factors are more common in people with schizophrenia than in the general population.
Methods
Study population and data sources
This study compared the incidence of cancer in people in Sweden diagnosed with schizophrenia with the incidence of cancer in the total population of Sweden between 1990 and 2013. Schizophrenia diagnoses were obtained from the National Patient Register and incident cancer diagnoses from three nationwide registers: the Cancer Register, the National Patient Register and the Cause of Death Register.
Identification of patients with schizophrenia
The National Patient Register, which contains comprehensive information on psychiatric inpatient care nationwide from 1973 onward, was used to identify all people 15 years or older who were admitted to the hospital and received a main diagnosis of schizophrenia between 1 January 1973 and 31 December 2013 (n = 137 535). Diagnoses of schizophrenia were identified using WHO's International Statistical Classification of Diseases (ICD) ICD-8 and ICD-9 diagnosis codes 295, 297 and 298 (1973–1996) and ICD-10 diagnosis codes F20 to F29 (1997–2013). When measured as the proportion of true cases, using chart review as the gold standard, coverage of schizophrenia diagnoses in the National Patient Register is 84% (Dalman et al., Reference Dalman, Broms, Cullberg and Alleback2002; Nesvåg et al., Reference Nesvåg, Jönsson, Bakken, Knudsen, Bjella, Reichborn-Kjennerud, Melle and Andreassen2017).
Identification of incident cancer cases
Information on cancer diagnoses from 1 January 1973 through 31 December 2013 was obtained from the Swedish Cancer Register, National Patient Register and Cause of Death Register (Ludvigsson et al., Reference Ludvigsson, Almqvist, Bonamy, Ljung, Michaëlsson, Neovius, Stephansson and Ye2016). Individual-level data from these sources were linked via a pseudonymised version of the personal identification number, assigned to all Swedish citizens and permanent residents. When an individual had a diagnosis of the same cancer in more than one register, the earliest diagnosis was used. We used 1 January 1973 to 31 December 1989 as a wash-out period to eliminate people diagnosed with cancer prior to the start of the study.
The Swedish Cancer Register gathers comprehensive data on diagnoses of cancer in the whole population of Sweden (Barlow et al., Reference Barlow, Westergren, Holmberg and Talback2009). The National Patient Register includes nationwide coverage of inpatient diagnoses of somatic diseases from 1987. The Cause of Death Register, established in 1961, includes data on cause(s) of death for all people registered in Sweden, including information from death certificates about date of death and main (underlying) and additional causes of death. The ICD-7 (Cancer Register) and ICD-9 and ICD-10 codes (National Patient Register and Cause of Death Register) are given in Table 2.
Study population and follow-up
People with diagnosed schizophrenia were followed up starting on the date of their first hospital admission for schizophrenia or 1 January 1990, whichever came last. Follow-up ended on the earliest of the following four dates: date of cancer diagnosis, date of death, date of emigration or 31 December 2013. Of the 137 535 people diagnosed with schizophrenia between 1973 and 2013, a total of 20 979 died and 5250 were diagnosed with cancer before the start of the study period in 1990, leaving 111 306 people in the schizophrenia cohort.
For the total population of Sweden (the comparison group), we obtained the number of people for each year in the study period, stratified by sex and age group, from Statistics Sweden, the Swedish national statistical agency.
Statistical analysis
The overall and site-specific cancer incidence rates in people with schizophrenia were compared with incidence rates in the general population, each calculated as the ratio of the number of incident cases to the number of person-years of follow-up. Poisson regression models were used to compare overall and site-specific cancer incidence rates in people with schizophrenia to those of the general population by estimating incidence rate ratios (IRRs) with 95% confidence intervals (CIs). The logarithm of the person-years of follow-up was used as the offset parameter. All models were adjusted for sex, calendar year and age at the time of follow-up in 5-year groups. IRRs were also estimated separately for men and women, by study period (1990–1996, 1997–2004 and 2005–2013) and by age group (15–39, 40–65 and 65 and older).
Results
The 111 306 people with schizophrenia contributed a total of 1 424 829 person-years of follow-up (Table 1). They were predominantly middle-aged (mean [s.d.] age, 49 ± 20 years) and female (53%).
Demographic and follow-up characteristics of people with schizophrenia in Sweden, in total and by sex, from 1990 through 2013
s.d., standard deviation.
Overall incidence of cancer
Among those with diagnosed schizophrenia, a total of 11 670 cases of cancer were identified (Table 2). There was no significant difference in the overall incidence of cancer compared to the general population (IRR 1.02, 95% CI 0.91–1.13). No significant differences in IRRs of overall cancer were found by age group or period (data not shown).
Incidence rate ratios (IRRs) of cancer in people with schizophrenia in Sweden from 1990 through 2013a
a IRRs were estimated by using Poisson regression models comparing overall and site-specific cancer incidence rates in people with schizophrenia to those of the general population. The reference group was the general population of Sweden. Lung: ICD-7: 1621, ICD-9: 162C-162D, 162W, 162X, ICD-10: C34; Esophagus: ICD-7: 150, ICD-9: 150, ICD-10: C15; Pancreas: ICD-7: 157, ICD-9: 157, ICD-10: C25; Stomach: ICD-7: 151, ICD-9: 151, ICD-10: C16; Colon: ICD-7: 153, ICD-9: 153, ICD-10: C18; Prostate: ICD-7: 177, ICD-9: 185, ICD-10: C61; Breast: ICD-7: 170, ICD-9: 174, ICD-10: C50.
Sex-stratified analyses showed a slightly decreased incidence in men with schizophrenia (IRR 0.93, 95% CI 0.89–0.98) and a slightly increased incidence in women with schizophrenia (IRR 1.11, 95% CI 1.08–1.15). The incidence of cancer was lower in men with schizophrenia than in men in the general population during the third period (2005–2013, IRR 0.89, 95% CI 0.81–0.96) but not the first two (1990–1996 and 1997–2004). The incidence of cancer remained higher in women with schizophrenia than in women in the general population during all three periods (data not shown).
The overall incidence of cancer in the age group 75 years and older was lower in people with schizophrenia (IRR 0.90, 95% CI 0.86–0.94). This pattern can also be seen in Fig. 1a. When stratified by sex, the overall incidence of cancer was lower in men with schizophrenia in the age group 65 years and older (IRR 0.86, 95% CI 0.80–0.92) (Fig. 1b). However, after an additional analysis that excluded prostate cancer, the lower incidence in this age group disappeared (IRR 0.96, 95% CI 0.92–1.02), and in the 40–64 years age group, a higher cancer incidence was observed among men with schizophrenia (IRR 1.26, 95% CI 1.19–1.33). The overall incidence of cancer was significantly higher in women with schizophrenia who were 40–64 years (IRR 1.22, 95% CI 1.16–1.28) and 65 years and older (IRR 1.05, 95% CI 1.02–1.09), than in the general population (Fig. 1c).
Incidence rate ratios (IRRs) of any cancer in people with schizophrenia and in the general population by age and sex,1990 through 2013.
Site-specific incidence of cancer
People with schizophrenia had a significantly higher incidence of cancers of the lung, oesophagus, pancreas and breast than people in the general population (Table 2). On the other hand, men with schizophrenia had a lower incidence of prostate cancer (IRR 0.66, 95% CI 0.55–0.79). There was no significant association between schizophrenia and incidence of cancer of the stomach or colon. Significantly higher incidence of oesophageal cancer and of pancreatic cancer was observed in men only.
After stratifying for time period (Table 3), we found that women with schizophrenia had an excess risk of breast cancer in all three periods (1990–1996, IRR 1.22, 95% CI 1.09–1.37; 1997–2004, IRR 1.17, 95% CI 1.06–1.30; and 2005–2013, IRR 1.18, 95% CI 1.08–1.30). The incidence of lung cancer was elevated in people with schizophrenia during the second (IRR 1.37, 95% CI 1.14–1.65) and third (IRR 1.64, 95% CI 1.41–1.89) periods of the study. Similarly, the incidence of oesophageal cancer was significantly higher in people with schizophrenia during the second (IRR 1.39, 95% CI 1.08–1.79) and third (IRR 1.29, 95% CI 1.01–1.63) study periods. The incidence of prostate cancer was decreased in men with schizophrenia during the second (IRR 0.67, 95% CI 0.48–0.93) and third (IRR 0.60, 95% CI 0.45–0.80) study periods.
Incidence rate ratios (IRRs) of cancer in people with schizophrenia in Sweden from 1990 through 2013 by perioda
a IRRs were estimated by using Poisson regression models comparing overall and site-specific cancer incidence rates in people with schizophrenia to those of the general population. The reference group was the general population of Sweden.
In analyses that were stratified by age group, the incidence of lung cancer was elevated in people with schizophrenia across all groups, but the incidence estimates decreased with increasing age strata (15–39 years, IRR 2.49, 95% CI 1.50–4.11; 40–64 years, IRR 1.90, 95% CI 1.67–2.15; and 65 years or older, IRR 1.21, 95% CI 1.05–1.39). There was an excess incidence of breast cancer in women with schizophrenia aged 40–64 years (IRR 1.19, 95% CI 1.09–1.29) and 65 years and older (IRR 1.21, 95% CI 1.10–1.32). The incidence of pancreatic cancer was significantly increased in people with schizophrenia between the ages of 15 and 39 years (IRR 2.93, 95% CI 1.16–2.31) and 40–64 years (IRR 1.31, 95% CI 1.10–1.56). The incidences of oesophageal (IRR 1.53, 95% CI 1.21–1.93) and stomach cancer (IRR 1.43, 95% CI 1.17–1.74) were significantly higher in people with schizophrenia only in the 40–64 years age group. The incidence of prostate cancer was significantly lower in men with schizophrenia who were 40–64 (IRR 0.54, 95% CI 0.44–0.66) and 65 or older (IRR 0.70, 95% CI 0.56–0.88), whereas the incidence of colon cancer was significantly lower in people with schizophrenia only in those 65 years or older (IRR 0.90, 95% CI 0.83–0.97).
Discussion
Main findings
In this population-based study, we found the same overall risk of cancer in people with schizophrenia as in the general population. However, we found a higher overall cancer risk among women with schizophrenia. The overall cancer risk for men was reduced among men with schizophrenia but the reduced risk disappeared when excluding prostate cancer from the analysis. We found a pattern of relative incidence rates among schizophrenia patients being higher in lower age groups when stratifying the analyses for age. A notable exception was observed for prostate cancer, where relative incidence rates were lower among younger men with schizophrenia. People with schizophrenia had a higher risk of lung, oesophageal and pancreatic cancer, women with schizophrenia had a higher risk of breast cancer, and men with schizophrenia had a lower risk of prostate cancer than the general population. Also some noteworthy differences in the overall and site-specific incidences of cancer by age category and by sex were observed.
The increased relative incidences in the schizophrenic population observed for lung, oesophageal, pancreatic and breast cancer were expected due to the higher prevalence of heavy smoking, alcohol use, obesity and lack of exercise in this population (Brown et al., Reference Brown, Birtwistle, Roe and Thompson1999; von Hausswolff-Juhlin et al., Reference von Hausswolff-Juhlin, Bjartveit, Lindström and Jones2009; Hartz et al., Reference Hartz, Pato, Medeiros, Cavazos-Rehg, Sobell, Knowles, Bierut and Pato2014; Hunt et al., Reference Hunt, Large, Cleary, Lai and Saunders2018; Jakobsen et al., Reference Jakobsen, Speyer, Nørgaard, Karlsen, Hjorthøj, Krogh, Mors, Nordentoft and Toft2018). The decreased incidence of prostate cancer compared to the general population can probably be explained by lower rates of detection by opportunistic prostate cancer screening. Prostate cancer screening is not part of the national screening programme in Sweden but testing is available at low cost within the Swedish health care system at patient's request.
Comparison with previous studies
Our finding of no excess overall risk of cancer associated with schizophrenia is broadly consistent with the findings of a meta-analysis of six studies that was published in 2008 (Catts et al., Reference Catts, Catts, O'Toole and Frost2008) but contrasts with the results of a more recent and larger meta-analysis of 16 cohort studies that found a small but statistically significant decreased risk of cancer in people with schizophrenia (Li et al., Reference Li, Li, Yu, Zheng, Sun, Lu, Zhang, Li and Bi2018). The inconsistencies in the conclusions of these two meta-analyses reflect the inconsistencies in the results of the individual studies. Indeed, in the meta-analysis by Li et al. (Reference Li, Li, Yu, Zheng, Sun, Lu, Zhang, Li and Bi2018), the percentage of total variation across studies was more than 90%, which indicates a high degree of inconsistency in the results of the individual studies (Higgins et al., Reference Higgins, Thompson, Deeks and Altman2003). Li et al. (Reference Li, Li, Yu, Zheng, Sun, Lu, Zhang, Li and Bi2018) advised that incidence risk ratios should be calculated for individual cancer types and separately for men and women.
Similar to the pooled analyses (Li et al., Reference Li, Li, Yu, Zheng, Sun, Lu, Zhang, Li and Bi2018) and an Israeli study (Agay et al., Reference Agay, Flaks-Manov, NItzan, Hoshen, Levkovitz and Munitz2017), we found a significantly lower risk of prostate cancer in men and a significantly higher risk of lung cancer in women with schizophrenia. In line with the findings from two meta-analyses of observational studies that focused on the association between schizophrenia and female breast cancer (Xiping et al., Reference Xiping, Shuai, Feijiang, Bo, Shifeng and Qihui2018; Zhuo and Triplett, Reference Zhuo and Triplett2018), we found a higher incidence of breast cancer in women with schizophrenia. Our findings are also consistent with two more recently-published population-based cohort studies that documented significantly higher risk of newly-diagnosed breast cancer in women with schizophrenia (Wu et al., Reference Wu, Wang, Lin and Kao2017; Chen et al., Reference Chen, Hung, Chen, Yang, Pan, Chen and Kuo2018). Few additional noteworthy sex differences in the risk of specific cancers in people with schizophrenia were observed in our study. In summary, the observations in our study are broadly consistent with recently-published pooled analyses of data from cohort studies investigating the sex-specific risks of individual cancer subtypes in people with schizophrenia.
Some of the cancer types that were the focus of this study were chosen based primarily on their association with adverse lifestyle factors that are also highly-prevalent in people with schizophrenia. For instance, a population-based retrospective cohort study of people with diagnosed mental health disorders found significant associations between female breast cancer and alcohol use and the presence of metabolic syndrome; between lung cancer and tobacco use; between oesophageal cancer and tobacco and alcohol use; and between pancreatic cancer and the use of tobacco (Hung et al., Reference Hung, Yang, Huang, Lung, Lin, Chen, Kuo and Chen2014). These results are consistent with the extensive literature that identifies lifestyle factors such as unhealthy diet, excessive body weight, physical inactivity, excessive alcohol consumption and smoking behaviours as modifiable risk factors for developing breast, prostate, lung and colon cancers in the broader population (Khan et al., Reference Khan, Afaq and Mukhtar2010; Weiderpass, Reference Weiderpass2010) and for reducing cancer-related deaths (Islami et al., Reference Islami, Goding Sauer, Miller, Siegel, Fedewa, Jacobs, McCullough, Patel, Ma, Soerjomataram, Flanders, Brawley, Gapstur and Jemal2018). We lacked specific information on the prevalence of unhealthy lifestyle-related risk factors among people with schizophrenia residing in Sweden. A national register study that used 1987–2010 data from the entire Swedish population aged 15 years or older showed that people with diagnosed schizophrenia had a threefold higher mortality from cardiovascular diseases than people in the general population (Westman et al., Reference Westman, Eriksson, Gissler, Hällgren, Prieto, Bobo, Frye, Erlinge, Alfredsson and Ösby2018). Inasmuch as smoking, alcohol consumption, poor diet and sedentary lifestyle are risk factors common to both cardiovascular diseases and lifestyle-related cancers, the high prevalence of these risk factors in people with schizophrenia in other parts of the world highlights the considerable potential for reducing the risk of lifestyle-related cancers as well as premature death from cardiovascular causes worldwide (Regier et al., Reference Regier, Fermer, Rae, Locke, Keith, Judd and Goodwin1990; Hung et al., Reference Hung, Yang, Huang, Lung, Lin, Chen, Kuo and Chen2014; Maremmani et al., Reference Maremmani, Bacciardi, Gehring, Cambioli, Schutz, Jang and Drausz2017; Vancamfort et al., Reference Vancampfort, Firth, Schuch, Rosenbaum, Mugisha, Hallgren, Probst, Ward, Gaughran, De Hert, Carvalho and Stubbs2017; Firth et al., Reference Firth, Stubbs, Teasdale, Ward, Veronese, Shivappa, Hebert, Berk, Yung and Sarris2018; Jakobsen et al., Reference Jakobsen, Speyer, Nørgaard, Karlsen, Hjorthøj, Krogh, Mors, Nordentoft and Toft2018).
Our study found that people with schizophrenia had a significantly higher incidence of oesophageal cancer. The risk was significantly increased for men but not women. In a nested case–control study that included 40 441 incident cases of six different types of cancer, researchers found no higher risk of gastroesophageal cancer in people with schizophrenia (Hippisley-Cox et al., Reference Hippisley-Cox, Vinogradova, Coupland and Parker2007). In that study, gastric and oesophageal cancers were combined, whereas in our study, they were analysed separately. No other population-based studies have reported the comparative risks of oesophageal cancer, discretely, in people with schizophrenia.
Our study also provides new information about schizophrenia and the risk of pancreatic cancer. We observed an increased risk of pancreatic cancer in people with schizophrenia. Stratification by sex showed an increased risk in men but not in women. We are aware of only one nationwide, population-based cohort study of the risk of pancreatic cancer in people with schizophrenia (Lin et al., Reference Lin, Lane, Chen, Wu, Wu and Wu2013a). That study showed a lower risk of pancreatic cancer in patients with schizophrenia than in the general population of Taiwan. They excluded metastatic malignancies from their analyses to reduce misclassification of the primary tumour site. However, because people with schizophrenia are typically diagnosed at a later stage of cancer (Kisely et al., Reference Kisely, Sadek, MacKenzie, Lawrence and Campbell2008), excluding metastatic malignancies may have led to an underestimation of cancer diagnoses in people with schizophrenia.
In our study, we observed a decreased overall cancer risk in people with schizophrenia 75 years and older. This observation is in line with findings from prior research showing that the incidence rates of cancer in people with schizophrenia may decline with increasing age (Dalton et al., Reference Dalton, Laursen, Mellemkjaer, Johansen and Mortensen2004; Lin et al., Reference Lin, Lane, Chen, Wu, Wu and Wu2013a, Reference Lin, Chen, Kuo, Jaiteh, Wu, Lo and Li2013b). The underlying causes of this age-related trend are unknown, but may be caused by selection where the small fraction of the schizophrenia population that reaches high age are physically healthier or have less risk factors than the general population of the same age. Cancer and cardiovascular disease, the other leading cause of death in Sweden, share several risk factors, such as smoking, alcohol use, obesity and physical inactivity. If schizophrenia modifies the effect of risk factors common between cancer and cardiovascular disease such that the effect on the risk of death is larger in people with schizophrenia, the prevalence of risk factors will decrease faster among people with schizophrenia as the populations age. We suggest two possible mechanisms through which schizophrenia could modify the effect of risk factors: (1) by increasing the probability of a dichotomous distribution of the risk factor, for example, smokers tending to be heavy smokers and obese people tending to be severely obese; and (2) increasing the probability of having a combination of risk factors. However, the Swedish national health register data do not include information on exposure to such lifestyle factors and we did not address the relative impact of early mortality from non-cancer-related causes on the incidence of new cancer diagnoses in this work.
Several lines of evidence suggest that people with schizophrenia may experience accelerated ageing (Kirkpatrick et al., Reference Kirkpatrick, Messias, Harvey, Fernandez-Egea and Bowie2008; Kirkpatrick and Kennedy, Reference Kirkpatrick and Kennedy2018). These include earlier manifestations of cognitive decline, diabetes and other age-associated chronic diseases (Kirkpatrick et al., Reference Kirkpatrick, Messias, Harvey, Fernandez-Egea and Bowie2008), as well as the early expression of a wide variety of biomarkers related to the ageing process (Kirkpatrick and Kennedy, Reference Kirkpatrick and Kennedy2018). It is not clear whether a potentially heightened risk of some types of cancers in younger and middle-aged people with schizophrenia can be attributed to accelerated ageing.
Strengths and limitations
The Swedish Cancer Register has nationwide coverage (Barlow et al., Reference Barlow, Westergren, Holmberg and Talback2009) and is well-suited for measuring cancer incidence in the general population. However, the register's completeness of incidence in people with schizophrenia may be limited. Underreporting is more likely for those whose histology or cytology verification is missing, which most commonly occurs when cancer is diagnosed at an advanced stage and the patient receives only palliative care (Barlow et al., Reference Barlow, Westergren, Holmberg and Talback2009). People with schizophrenia have low rates of participation in general health and cancer screening programmes (Fujiwara et al., Reference Fujiwara, Inagaki, Nakaya, Fujimori, Higuchi, Hayashibara, So, Kakeda, Kodama, Uchitomi and Yamada2017; Hwong et al., Reference Hwong, Wang, Bent and Mangurian2020; Solmi et al., Reference Solmi, Firth, Miola, Fornaro, Frison, Fusar-Poli, Dragioti, Shin, Carvalho, Stubbs, Koyanagi, Kisely and Correll2020), and delayed and late-stage cancer diagnoses are common in this patient population (Farasatpour et al., Reference Farasatpour, Janardhan, Williams, Margenthaler, Virgo and Johnson2013). To compensate the underreporting in the Swedish Cancer Register and minimise possible differential completeness in reporting, we used additional data on incident cancers from other nationwide registers, including the National Patient Register or the Swedish Cause of Death Register.
To the best of our knowledge, the current study is the largest to date with respect to the number of individuals with diagnosed schizophrenia. An additional strength of the study was the analysis by calendar period of follow-up. The mean (49 years) and median (45 years) age and age span (up to more than 80 years) of the schizophrenia cohort in the study were also advantageous, as they allowed us to compare incidence in age groups for which the risk of incident cancer is most relevant, including advanced age.
There are also limitations to consider. This study used data from computerised, linked registers. These data were collected for purposes other than for research, and may be subject to misclassification. Additionally, given that this was a register-based study, our findings are restricted to the incidence of diagnosed cancer. Even though the underlying population in this study had universal health coverage, the true incidence of cancer is likely obscured by low participation in general preventive health services and cancer screening programmes that is frequently observed in people with schizophrenia (Mitchell et al., Reference Mitchell, Lord and Malone2012; Liu et al., Reference Liu, Daumit, Dua, Aquila, Charlson, Cuijpers, Druss, Dudek, Freeman, Fujii, Gaebel, Hegerl, Levav, Munk Laursen, Ma, Maj, Elena Medina-Mora, Nordentoft, Prabhakaran, Pratt, Prince, Rangaswamy, Shiers, Susser, Thornicroft, Wahlbeck, Fekadu Wassie, Whiteford and Saxena2017; Irwin et al., Reference Irwin, Steffens, Yoon, Flores, Knight, Pirl, Freudenreich, Henderson and Park2019). This bias would be especially problematic when studying cancers with less acute courses (e.g. prostate, skin or thyroid cancer), while this bias would be less of a concern when studying cancers that are often detected when acute symptoms are already present (e.g. lung, oesophagus and stomach cancers). Although the schizophrenia cohort in this study was large, because of sample size limitations, we were not able to study the comparative risks of all cancer types, including important but rarer malignancies. Some of the statistically significant associations between schizophrenia and some site-specific cancers, such as the results on oesophageal and pancreatic cancer, must be interpreted with caution given small effects (IRR near 1) and evidence of low precision (wide 95% CIs). We were unable to examine the impacts of a variety of susceptibility factors on cancer incidence in this study, including family history, genetic characteristics, use of antipsychotic drugs and other medications, reproductive history and lifestyle factors. We suggest national health information systems should include comprehensive registration on primary health care visits, and collection of these data should include also information on BMI, smoking and alcohol consumption. Further, our data lacked information on the stage of cancer. This is an important consideration given the likelihood that people with schizophrenia present with a more advanced stage of cancer at the time of diagnosis (Toender et al., Reference Toender, Munk-Olsen, Vestergaard, Larsen, Suppli, Dalton, Vedsted, Nordentoft, Mortensen and Laursen2018) – a factor that has been associated with worse cancer survival in people with pre-existing mental disorders (Davis et al., Reference Davis, Bogner, Coburn, Hanna, Kurdyak, Groome and Mahar2020). Others have documented a significantly higher proportion of individuals with evidence of metastatic disease at presentation in people with psychiatric illness (Kisely et al., Reference Kisely, Crowe and Lawrence2013). The availability of information on cancer stage at diagnosis will be an important consideration for future population-based studies of cancer incidence and survival in people with severe mental illnesses as it could add information about the mechanisms behind the high cancer mortality among schizophrenia patients. In our study, follow-up was available until 2013, and we did not have complete data for the analysis of cancer risk beyond that time. Finally, all study data came from the population of Sweden, so the risk estimates may not generalise to people living in other parts of the world.
Conclusions
There was no overall higher risk of cancer in people with schizophrenia than in the general population in this population-based study. However, people with schizophrenia had a higher risk of lung, oesophageal and pancreatic cancer; women with schizophrenia had a higher risk of breast cancer; and men with schizophrenia had a lower risk of prostate cancer than the equivalent groups of people in the general population. The observed differences in incidence between schizophrenia patients and the general population correspond to known differences in lifestyle factors or, for prostate cancer, expected differences in tumour detection through differential participation in opportunistic screening outside of the national screening programmes. Some noteworthy sex-specific differences in cancer risk were observed. A lower overall risk of cancer was observed in people with schizophrenia aged 75 years or more than in the same age group in the general population.
Data
The Swedish register data have been given for this specific study, and the data cannot be shared without authorisation from the register keepers.
Financial support
The study has been funded by NIMH, AHRQ and the Mayo Foundation for Medical Education and Research in the USA.
Conflict of interest
The authors report no conflict of interest.
Open access
